Fortress Biotech (STU:CNB1) Short-Term Debt: €4.34 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CNB1 Fortress Biotech Inc STU:CNB1
46 GF Score
Price €1.93
GF Value €0.89
! 6 Warning Signs
View Full Analysis

What is Fortress Biotech Short-Term Debt?

Fortress Biotech STU:CNB1 46 Short-Term Debt is €4.34 Mil as of Jun. 2026. GuruFocus rates STU:CNB1 with a GF Score™ of 46/100 and a GF Value™ of €0.89. The stock has 6 warning signs investors should review.

Fortress Biotech's Short-Term Debt for the quarter that ended in Jun. 2026 was €4.34 Mil.

Fortress Biotech's quarterly Short-Term Debt increased from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€2.16 Mil) and increased from Mar. 2026 (€2.16 Mil) to Jun. 2026 (€4.34 Mil).

Fortress Biotech's annual Short-Term Debt declined from Dec. 2023 (€2.75 Mil) to Dec. 2024 (€0.60 Mil) and declined from Dec. 2024 (€0.60 Mil) to Dec. 2025 (€0.00 Mil).

Fortress Biotech Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Fortress Biotech Short-Term Debt Related Terms

Fortress Biotech Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Short-Term Debt Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.71 9.61 2.75 0.60 0.00

Fortress Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.25 4.79 0.00 2.16 4.34
STU:CNB1
46GF Score
Fortress Biotech Inc STU:CNB1
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €4.34 Mil mean?
Fortress Biotech (STU:CNB1) has a Short-Term Debt of €4.34 Mil as of Jun. 2026.
Is Fortress Biotech's Short-Term Debt too high?
Fortress Biotech's current Short-Term Debt is €4.34 Mil. Overall, Fortress Biotech has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Short-Term Debt compare to PMN and VANI?
Fortress Biotech's Short-Term Debt of €4.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Fortress Biotech's current Short-Term Debt is €4.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current Short-Term Debt of €4.34 Mil. The stock's GF Value™ is €0.89, compared to a current price of €1.93 — trading 116.9% above its estimated fair value. The current Short-Term Debt is €4.34 Mil. Fortress Biotech's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current Short-Term Debt is €4.34 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (STU:CNB1) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of €1.93 is trading 116.9% above its estimated GF Value™ of €0.89.

Key valuation signals for STU:CNB1:

  • Short-Term Debt: €4.34 Mil
  • GF Value™: €0.89 vs. price of €1.93 (116.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
46GF Score

Get the complete analysis for STU:CNB1

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€0.89
GF Value